Death Receptor 3 (TNFRSF25) Increases Mineral Apposition by Osteoblasts and Region Specific New Bone Formation in the Axial Skeleton of Male DBA/1 Mice

Objectives. Genome wide association studies identified TNFSF member TNF-like protein 1A (TL1A, TNFSF15) as a potential modulator of ankylosing spondylitis (AS). TL1A is the only confirmed TNFSF ligand of death receptor 3 (DR3, TNFRSF25); however, its role in disease pathology is not characterised. We evaluated DR3's role in controlling osteoblast- (OB-) dependent bone formation in vitro and in vivo. Methods. Osteoprogenitor cells and OB were cultured from male DR3-deficient (DR3ko) and wild-type (DR3wt) DBA/1 mice. DR3 and RANKL expression were tested by flow cytometry. Alkaline phosphatase and mineralization were quantified. Osteopontin, osteoprotegerin, and pro MMP-9 were measured by ELISA. A fluorescent probe (BoneTag) was used to measure in vivo mineralization in 10-month-old mice. Results. DR3 was expressed on osteoprogenitors and OB from DR3wt mice. Alkaline phosphatase, osteopontin, and mineral apposition were significantly elevated in DR3wt cultures. Levels of RANKL were comparable whilst osteoprotegerin was significantly increased in DR3wt cultures. In vivo incorporation of BoneTag was significantly lower in the thoracic vertebrae of 10-month-old DR3ko mice. Conclusions. These data identify new roles for DR3 in regulating OB-dependent bone mineral apposition. They potentially begin to explain the atypical pattern of new bone formation observed in the axial skeleton of grouped, aging DBA/1 mice.

[1]  Stephen R. Clark,et al.  Regulation of Early Cartilage Destruction in Inflammatory Arthritis by Death Receptor 3 , 2014, Arthritis & rheumatology.

[2]  P. Sfikakis,et al.  Increased levels of soluble TNF-like cytokine 1A in ankylosing spondylitis. , 2013, Rheumatology.

[3]  I. Humphreys,et al.  The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4+ and CD8+ T‐cell immunity , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  T. Ślebioda,et al.  Triggering of TNFRSF25 promotes CD8+ T‐cell responses and anti‐tumor immunity , 2011, European journal of immunology.

[5]  Chang-Youh Tsai,et al.  Soluble receptor activator of nuclear factor-κB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation , 2010, Clinical Rheumatology.

[6]  G. Karsenty,et al.  Genetic control of bone formation. , 2009, Annual review of cell and developmental biology.

[7]  S. Heath,et al.  Comprehensive Linkage and Association Analyses Identify Haplotype, Near to the TNFSF15 Gene, Significantly Associated with Spondyloarthritis , 2009, PLoS genetics.

[8]  T. Ślebioda,et al.  The Death Receptor 3–TNF-like protein 1A pathway drives adverse bone pathology in inflammatory arthritis , 2008, The Journal of experimental medicine.

[9]  E. Shevach,et al.  The TNF-family receptor DR3 is essential for diverse T cell-mediated inflammatory diseases. , 2008, Immunity.

[10]  S. Teitelbaum.  Osteoclasts: what do they do and how do they do it? , 2007, The American journal of pathology.

[11]  Yanan Li,et al.  Death receptor‐3 mediates apoptosis in human osteoblasts under narrowly regulated conditions , 2006, Journal of cellular physiology.

[12]  A. Boonen,et al.  Identification of the most common problems by patients with ankylosing spondylitis using the international classification of functioning, disability and health. , 2006, The Journal of rheumatology.

[13]  F. Cominelli,et al.  Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[14]  S. Christakos,et al.  The Vitamin D Receptor, Runx2, and the Notch Signaling Pathway Cooperate in the Transcriptional Regulation of Osteopontin* , 2005, Journal of Biological Chemistry.

[15]  B. Kwon,et al.  Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis. , 2005, Cytokine.

[16]  F. Luyten,et al.  Ankylosing enthesitis, dactylitis, and onychoperiostitis in male DBA/1 mice: a model of psoriatic arthritis , 2004, Annals of the rheumatic diseases.

[17]  Claire K. Inman,et al.  The Osteoblast Transcription Factor Runx2 Is Expressed in Mammary Epithelial Cells and Mediates osteopontin Expression* , 2003, Journal of Biological Chemistry.

[18]  Yanan Li,et al.  Expression and function of TNF-family proteins and receptors in human osteoblasts. , 2003, Bone.

[19]  P. Ory,et al.  Radiography in the assessment of musculoskeletal conditions. , 2003, Best practice & research. Clinical rheumatology.

[20]  Muhammad Asim Khan,et al.  Update on Spondyloarthropathies , 2002, Annals of Internal Medicine.

[21]  J. Deng,et al.  The Novel Zinc Finger-Containing Transcription Factor Osterix Is Required for Osteoblast Differentiation and Bone Formation , 2002, Cell.

[22]  K. Pfeiffer,et al.  Circulating cytotoxic CD8+ CD28- T cells in ankylosing spondylitis , 2001, Arthritis research.

[23]  A. Thern,et al.  DR3 Regulates Negative Selection during Thymocyte Development , 2001, Molecular and Cellular Biology.

[24]  B. Kwon,et al.  Tumor necrosis factor receptor superfamily 12 may destabilize atherosclerotic plaques by inducing matrix metalloproteinases. , 2001, Japanese circulation journal.

[25]  P. Romano,et al.  The Expression of Metalloproteinase‐2, −9, and −14 and of Tissue Inhibitors‐1 and −2 Is Developmentally Modulated During Osteogenesis In Vitro, the Mature Osteoblastic Phenotype Expressing Metalloproteinase‐14 , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  S. Teitelbaum,et al.  Bone resorption by osteoclasts. , 2000, Science.

[27]  G. Karsenty,et al.  Osf2/Cbfa1: A Transcriptional Activator of Osteoblast Differentiation , 1997, Cell.

[28]  Makoto Sato,et al.  Targeted Disruption of Cbfa1 Results in a Complete Lack of Bone Formation owing to Maturational Arrest of Osteoblasts , 1997, Cell.

[29]  T. Schacker,et al.  Clinical and Epidemiologic Features of Primary HIV Infection , 1996, Annals of Internal Medicine.

[30]  S. Jonjić,et al.  Site-restricted persistent cytomegalovirus infection after selective long-term depletion of CD4+ T lymphocytes , 1989, The Journal of experimental medicine.

[31]  Dr Syed Yousuf Ali,et al.  Psoriatic Arthritis A Systematic Review , 2015 .

[32]  Juan S. Uribe,et al.  A review of the pathogenesis of ankylosing spondylitis. , 2008, Neurosurgical focus.

[33]  Tutut Herawan,et al.  Computational and mathematical methods in medicine. , 2006, Computational and mathematical methods in medicine.